MSF reveals cost of its landmark TB clinical trial: €34 million

April 26, 2024

MSF urges public and non-profit actors to publish clinical trial costs to improve access to medical products for all. Geneva, 25 April 2024 - At the 5th WHO Pharmaceutical Pricing and Reimbursement Policies conference today, Doctors Without Borders/Médecins Sans Frontières...

Myanmar: I have defeated TB and I wish the same for other patients

April 8, 2024

Multi-drug resistant tuberculosis is one of the most complex types of tuberculosis you can get. As opposed to drug-sensitive, which responds well to the medication, multi-drug resistant tuberculosis, by its very name, is resistant to some of the drugs used...

Patient Stories: Ensuring recovery through timely, accurate drug-resistant tuberculosis testing

March 18, 2024

Ahmad, 11, from Tatlay Aali, a town in Gujranwala district, Pakistan, was diagnosed with tuberculosis (TB) when he was just five years old. "We’d never heard about this disease, nobody from our family ever had it. At the same time,...

MSF launches unprecedented project to tackle under-diagnosed tuberculosis among children

March 18, 2024

Tuberculosis (TB) in children is a silent scourge: one child dies of TB every three minutes and more than half of all children with TB are never diagnosed. Taking the opportunity of a set of new recommendations by the World...

MSF warns governments are failing to test, treat and prevent TB in children

November 14, 2023

Governments must immediately implement the latest WHO guidelines to stop children from dying from this deadly yet curable disease Geneva, 14 November 2023 - Médecins Sans Frontières/Doctors Without Borders (MSF)  welcomed the World Health Organization’s (WHO) ‘Roadmap towards ending TB in...

MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease

November 7, 2023

The World Health Organization’s (WHO) 2023 Global Tuberculosis (TB) Report released today shows that the estimated global incidence of TB in 2022 remains unacceptably high, including for the more difficult to treat form of this disease, drug-resistant TB (DR-TB). With...